Struggling With Great Stock Picks? Discover StockInvest.us Top Gems!
$2.31
-0.0100 (-0.431%)
At Close: May 09, 2024
Forecast Earnings Dividends Fundamentals Insider Trading Signals Historical Prices Predictions News Profile

Range Low Price High Price Comment
30 days $1.31 $4.00 Thursday, 9th May 2024 CYCC stock ended at $2.31. This is 0.431% less than the trading day before Wednesday, 8th May 2024. During the day the stock fluctuated 14.48% from a day low at $2.27 to a day high of $2.60.
90 days $1.31 $4.00
52 weeks $1.31 $13.20

Historical Cyclacel Pharmaceuticals prices

Date Open High Low Close Volume
Apr 14, 2020 $0.400 $0.404 $0.361 $0.387 374 645
Apr 13, 2020 $0.400 $0.400 $0.380 $0.400 83 306
Apr 09, 2020 $0.410 $0.420 $0.381 $0.390 56 209
Apr 08, 2020 $0.410 $0.410 $0.350 $0.400 86 924
Apr 07, 2020 $0.380 $0.400 $0.370 $0.375 34 697
Apr 06, 2020 $0.350 $0.400 $0.350 $0.380 46 809
Apr 03, 2020 $0.380 $0.380 $0.350 $0.372 35 537
Apr 02, 2020 $0.382 $0.382 $0.360 $0.361 16 791
Apr 01, 2020 $0.385 $0.385 $0.340 $0.370 31 923
Mar 31, 2020 $0.394 $0.400 $0.375 $0.386 66 246
Mar 30, 2020 $0.391 $0.391 $0.363 $0.375 61 492
Mar 27, 2020 $0.400 $0.400 $0.370 $0.385 27 330
Mar 26, 2020 $0.400 $0.438 $0.350 $0.401 214 226
Mar 25, 2020 $0.413 $0.413 $0.360 $0.395 165 552
Mar 24, 2020 $0.347 $0.365 $0.330 $0.365 224 855
Mar 23, 2020 $0.430 $0.430 $0.330 $0.333 100 928
Mar 20, 2020 $0.374 $0.400 $0.310 $0.330 408 687
Mar 19, 2020 $0.360 $0.410 $0.350 $0.379 100 515
Mar 18, 2020 $0.370 $0.400 $0.340 $0.360 88 087
Mar 17, 2020 $0.356 $0.383 $0.320 $0.370 97 651
Mar 16, 2020 $0.290 $0.400 $0.290 $0.350 267 809
Mar 13, 2020 $0.570 $0.570 $0.450 $0.480 125 130
Mar 12, 2020 $0.570 $0.574 $0.450 $0.480 234 408
Mar 11, 2020 $0.490 $0.550 $0.477 $0.540 482 768
Mar 10, 2020 $0.490 $0.500 $0.450 $0.478 122 129
Click to get the best stock tips daily for free!

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-... CYCC Profile

Golden Star

Ticker Date Change Price
WMT May 06 0.718% $59.87
UNP May 06 2.80% $239.21
JPM May 06 1.90% $192.00
INGR May 03 3.40% $114.56
BNDX May 03 0.247% $48.68
BBCA May 03 0.99% $65.44
ADTH May 03 5.86% $3.24
ASH May 03 1.78% $95.85
INVH May 03 0.90% $34.39
INTU May 03 0.502% $629.27
Unlock

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT